American Association for Cancer Research

Skip to Main Content

Table 1

Cases included in the study

	MLL^+ve(%^+ve)^a	MLL^−ve	MLL status NK^b	Total
Diagnosis
ALL	19 (53%)	17	13	49
AML	29 (66%)	15	30	74
Other^c	2 (40%)	3	8	13
Age
0–5 mo	18 (72%)	7	18	43
6–11 mo	14 (58%)	10	18	42
12–17 mo	18 (50%)	18	25	87
Gender
Female	28 (60%)	19	23	70
Male	22 (58%)	16	28	66
Region
Orient	18 (60%)	12	2	32
South America	22 (63%)	13	17	52
Europe	10 (50%)	10	32	52

	MLL^+ve(%^+ve)^a	MLL^−ve	MLL status NK^b	Total
Diagnosis
ALL	19 (53%)	17	13	49
AML	29 (66%)	15	30	74
Other^c	2 (40%)	3	8	13
Age
0–5 mo	18 (72%)	7	18	43
6–11 mo	14 (58%)	10	18	42
12–17 mo	18 (50%)	18	25	87
Gender
Female	28 (60%)	19	23	70
Male	22 (58%)	16	28	66
Region
Orient	18 (60%)	12	2	32
South America	22 (63%)	13	17	52
Europe	10 (50%)	10	32	52

Percentage of MLL^+ve of those cases with known MLL status.

NK, no diagnostic sample available or sample degraded.

Includes biphenotyoic.